This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ZIOPHARM Presents Promising Preclinical Pediatric Sarcoma Data With Oral And IV Palifosfamide At The 2011 CTOS/MSTS Meeting

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide (Zymafos™ or ZIO-201) in a pediatric sarcoma model. The data was detailed in an oral session of the 2011 meeting of the combined Connective Tissue Oncology Society (CTOS) Musculoskeletal Tumor Society (MSTS), being held October 26 – 29, 2011 in Chicago, IL.

The presentation, entitled “Palifosfamide, a Bifunctional DNA Alkylator, Inhibits Growth of Pediatric Sarcoma Xenografts Across a Wide Dose Range Following Oral and Parenteral Dosing,” addressed, among other findings, the impact of palifosfamide activity in the presence of overexpression of aldehyde dehydrogenase (ALDH), an enzyme thought to confer resistance to alkylators like cyclophosphamide and ifosfamide. The authors reported that palifosfamide, a bi-functional DNA-alkylator in class with ifosfamide, cyclophosphamide and bendamustine, did not exhibit ALDH resistance. This important finding, combined with the use of oral administration and a potentially favorable toxicity profile, are particularly relevant for the pediatric population.

In vivo modeling for the study was conducted in the Cancer Therapeutics Laboratory of the Alfred I. DuPont Hospital for Children. The authors included E. Anders Kolb, M.D., Director, Blood and Bone Marrow Transplantation and Head, Cancer Therapeutics Laboratory as lead author and Richard Gorlick, M.D., Vice Chairman of Pediatrics at Albert Einstein College and Chairman of the Children’s Oncology Group (COG) Bone Sarcoma Committee as senior author. Results showed that orally administered palifosfamide was found to have broad in vivo preclinical activity comparable to parenteral administration in an osteosarcoma model. This activity was measured by tumor growth delay, relative tumor volume (RTV) and event-free survival across all doses. Investigators also found palifosfamide active in xenografts with overexpressed levels of ALDH. Overexpression of ALDH is present in diverse tumor types including breast cancer, colon cancer, pancreas cancer, Ewing’s sarcoma and other cancers, and is a marker of cancer stem cells. Ongoing testing of dose and schedule in both sarcoma and breast cancer models will define future clinical evaluation of the oral form and was supported through mathematical applied Norton-Simon modeling, as established by Larry Norton, M.D., deputy physician-in-chief for breast cancer programs, at Memorial Sloan-Kettering Cancer Center and an author of the study.

“The overexpression of ALDH in cancer cells may confer cancer stem cell-like activity and resistance to treatment, including chemotherapy and, in particular, ifosfamide and cyclophosphamide,” stated Dr. Kolb. “As a stabilized form of the active metabolite of ifosfamide, palifosfamide bypasses resistance mediated by ALDHs, in addition to conferring a potentially favorable toxicity profile compared to ifosfamide, which is known to generate toxic metabolites such as acrolein and chloroacetaldehyde. These results are compelling and merit further exploration in the clinic.”

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.14 0.14%
FB $98.92 -0.83%
GOOG $678.93 -0.56%
TSLA $149.13 0.77%
YHOO $26.80 -0.92%


Chart of I:DJI
DOW 16,016.78 -10.27 -0.06%
S&P 500 1,841.54 -11.90 -0.64%
NASDAQ 4,242.1510 -41.6020 -0.97%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs